Analytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucoma

Current Medical Research and Opinion

Volumn 21, Issue 11, 2005, Pages 1875-1883

  Holmstrom, Stefan ^a   Buchholz, Patricia ^a   Walt, John ^b   Wickstrøm, Jannie ^c   Aagren, Mark ^c  

^a ALLERGAN PLC   (United States)

^b Allergan   (United States)

^c Muusmann Research and Consulting   (Denmark)

Author keywords

Bimatoprost; Glaucoma; Intraocular pressure; Latanoprost; Timolol; Travoprost

Indexed keywords

BIMATOPROST; BRIMONIDINE; LATANOPROST; TIMOLOL; TRAVOPROST;

BIOAVAILABILITY; DRUG EFFICACY; EMBASE; HUMAN; HYPEREMIA; INTRAOCULAR PRESSURE; MEDLINE; OPEN ANGLE GLAUCOMA; REDUCTION; REVIEW;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AMIDES; CLINICAL TRIALS; CLOPROSTENOL; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; LIPIDS; PROSTAGLANDINS F, SYNTHETIC; RANDOMIZED CONTROLLED TRIALS; TIMOLOL; TREATMENT OUTCOME;

EID: 27944471710     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X65600     Document Type: Review

References (53)

1. Bankes JLK, Clinical Ophthalmology. Churchill Livingstone 1982, Chapter 12, ISBN 0443021570
2. Lee DA, Higginbotham EJ. Glaucoma and its treatment: a review. Am J Health Syst Pharm 2005;62:691-9
3. Friedman DS, Wolfs RC, O'Colmain BJ, et al. Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol 2004;122:532-8
4. Nordmann, JP, Touboul C, Auzanneeau N, et al. Vision related quality of life of French patients is affected by topical glaucoma treatment side effects. Poster presented at ISPOR, Annual European Congress, 2002
5. AGIS Investigators. The advanced glaucoma intervention study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000;130:490-1
6. Suzuki Y, Shirato S, Adachi M, et al. Risk factor for the progression of treated primary open angle glaucoma: A mulitvariate life-table analysis. Graefes Arch Clin Exp Ophthalmol 1999;237:463-7
7. Van der Valk R, Webers CAB, Schouten JSAG, et al. Intraocular pressure-lowering effects of all commonly used glaucoma drugs. Ophthalmology 2005;112:1177-85
8. Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology 1995;102:1743-52
9. Aim A, Villumsen J, Törnquist P, et al. Intraocular pressure-reducing effect of PhXA41 in patients with increased eye pressure. A one-month study. Ophthalmology 1993;100:1312-7
10. Aquino MV, Lat Luna M. The effect of latanoprost vs timolol on intraocular pressure in patients with glaucoma and ocular hypertension. Asian J Opthalmol 1999;1:3-7
11. Brandt JD, VanDenburgh AM, Chen K, et al. Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP: A 3-month clinical trial. Ophthalmology 2001;108:1023-31
12. Bron AM, Denis P, Nordmann JP, et al. Additive IOP-reducing effect of latanoprost in patients insufficiently controlled on timolol. Acta Ophthalmol Scand 2001;79:289-93
13. Bucci MG. Intraocular pressure-lowering effects of latanoprost monotherapy versus latanoprost or pilocarpine in combination with timolol: a randomized, observer-masked multicenter study in patients with open-angle glaucoma. Italian Latanoprost Study Group. J Glaucoma 1999;8:24-30
14. Camras CB. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology 1996;103:138-47
15. Cantor LB, WuDunn D, Cortes A, et al. Ocular hypotensive efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension. Surv Ophthalmol 2004;49:12-8
16. Chew PTK, Hung PT, Aung T. Efficacy of latanoprost in reducing intraocular pressure in patients with primary angle-closure glaucoma. Surv Ophthalmol 2002;47:125-8
17. Coleman AL, Lerner F, Bernstein P, et al. A 3-month randomized controlled trial of bimatoprost (LUMIGAN) versus combined timolol and dorzolamide (Cosopt) in patients with glaucoma or ocular hypertension. Ophthalmology 2003;110:2362-8
18. Diestelhorst M, Almegård B. Comparison of two fixed combinations of latanoprost and timolol in open-angle glaucoma. Graefes Arch Clin Exp Ophthalmol 1998;236:577-81
19. DuBiner H, Cooke D, Dirks M, et al. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost. Surv Ophthalmol 2001;45:353-60
20. Fechtner RD, Airaksinen PJ, Getson AJ, et al. COSOPT versus XALATAN study groups, efficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (COSOPT) versus 0.005% (XALATAN) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials. Acta Ophthalmol Scand 2004;82:42-8
21. Fellman RL, Sullivan EK, Ratliff M, et al. Travoprost Study Group, comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multicenter trial. Ophthalmology 2002;109:998-1008
22. Gandolfi S, Simmoms ST, Sturm R, et al. for the Bimatoprost Study Group 3. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertensions. Adv Ther 2001;18:110-21
23. Gandolfi SA, Cimino L. Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost. Ophthalmology 2003;110:609-14
24. García-Sánchez J, Rouland J-F, Spiegel D, et al. A comparison of the fixed combination of latanoprost and timolol with the unfixed combination of brimonidine and timolol in patients with elevated intraocular pressure. A six month, evaluator masked, multicentre study in Europe. Br J Ophthalmol 2004;88:877-83
25. Goldberg I, Cunha-Vaz J, Jakobsen JE, et al. International Travoprost Study Group, Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension. J Glaucoma 2001;10:414-22
26. Higginbotham EJ, Feldman R, Stiles M, et al. Latanoprost and timolol combination therapy vs monotherapy: One-year randomized trial. Arch Ophthal 2002;120:915-22
27. Jampel HD, Bacharach J, Sheu W-P, et al. Latanoprost/unoprostone Study Group, randomized clinical trial of latanoprost and unoprostone in patients with elevated intraocular pressure. Am J Ophthalmol 2002;134:863-71
28. Kjellgren D, Douglas G, Mikelberg FS, et al. The short-time effect of latanoprost on the intraocular pressure in normal pressure glaucoma. Acta Ophthalmol Scand 1995;73:233-6
29. Laibovitz RA, VanDenburgh AM, Felix C, et al. Comparison of the ocular hypotensive lipid AGN 192024 with timolol: dosing, efficacy, and safety evaluation of a novel compound for glaucoma management. Arch Ophthal 2001;119:994-1000
30. Manni G, Centofanti M, Parravano M, et al. A 6-month randomized clinical trial of bimatoprost 0.03% versus the association of timolol 0.5% and latanoprost 0.005% in glaucomatous patients. Graefes Arch Clin Exp Ophthalmol 2004;242:767-70
31. Mastropasqua, L, Carpineto P, Ciancaglini M, et al. A 12-month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucoma. Ophthalmology 1999; 106:550-5
32. Mishima HK, Masuda K, Kitazawa Y, et al. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study. Arch Ophthal 1996;114:929-32
33. Netland PA, Landry T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001;132:472-84
34. Netland PA, Michael M, Rosner SA, et al. Brimonidine purite and bimatoprost compared with timolol and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther 2003; 20:20-30
35. Noecker RS, Dirks MS, Choplin NT, et al. Latanoprost Study Group, A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol 2003;135:55-63
36. Nordmann JP, Söderström M, Rouland JF, et al. Comparison of the intraocular pressure lowering effect of latanoprost and a fixed combination of timolol-pilocarpine eye drops in patients insufficiently controlled with beta adrenergic antagonists. French Latanoprost Study Group, and the Swedish Latanoprost Study Group. Br J Ophthalmol 2000;84:181-5
37. Orengo-Nania S, Landry T, Von Tress M, et al. Travoprost Study Group, Evaluation of travoprost as adjunctive therapy in patients with uncontrolled intraocular pressure while using timolol 0.5%. Am J Ophthalmol 2001;132:860-8
38. Parrish RX, Palmberg P, Sheu W-P. XLT study group, A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 2003; 135:688-703
39. Pfeiffer N. European Latanoprost Fixed Combination Study Group, A comparison of the fixed combination of latanoprost and timolol with its individual components. Graefes Arch Clin Exp Ophthalmol 2002;240:893-9
40. Sherwood M, Brandt J. Bimatoprost Study Groups 1 and 2. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Surv Ophthalmol 2001;45:361-8
41. Shin DH, Feldman RM, Sheu W-P. Fixed Combination Latanoprost/Timolol Study Group. Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure. Ophthalmology 2004;111:276-82
42. Sihota R, Saxena R, Agarwal HC, et al. Peak pressures: crossover study of timolol and latanoprost. Eur J Ophthalmol 2003; 13:546-52
43. Stewart WC, Stewart JA, Day D, et al. Efficacy and safety of timolol maleate/latanoprost fixed combination versus timolol maleate and brimonidine given twice daily. Acta Ophthalmol Scand 2003;81:242-6
44. Susanna R, Giampani J, Borges AS, et al. A double-masked, randomized clinical trial comparing latanoprost with unoprostone in patients with open-angle glaucoma or ocular hypertension. Ophthalmology 2001;108:259-63
45. Thygesen J, Aaen K, Theodorsen F, et al. Short-term effect of latanoprost and timolol eye drops on tear fluid and the ocular surface in patients with primary open-angle glaucoma and ocular hypertension. Acta Ophthalmol Scand 2000;78:37-44
46. Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes. Ophthalmology 1993;100:1297-304
47. Walters TR, DuBiner HB, Carpenter SP, et al. 24-hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial. Surv Ophthalmol 2004;49:26-35
48. Watson P, Stjernschantz, J. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group. Ophthalmology 1996;103:126-37
49. Whitcup SM, Cantor LB, VanDenburgh AM, et al. A randomised, double masked, multicentre clinical trial comparing bimatoprost and timolol for the treatment of glaucoma and ocular hypertension. Br J Ophthalmol 2003;87:57-62
50. Cohen JS, Gross RL, Cheetham JK, et al. Two-year double-masked comparison of bimatoprost with timolol in patients with glaucoma or ocular hypertension. Surv Ophthalmol 2004; 49:45-52
51. Cantor L. Achieving low target pressures with todays glaucoma medications. Surv Ophthalmol 2003;48(Suppl 1):S8-16
52. Rosetti L, Fogagnolo ON. A meta-analysis of randomized clinical trials comparing the efficacy and safety of latanoprost, travoprost, and bimatoprost in reducing the intraocular pressure. Abstract presented at the 7th Scientific Meeting of the Association for Ocular Pharmacology and Therapeutics (AOPT), Catania, February 3-5, 2005
53. European Glaucoma Society. Terminology and guidelines for glaucoma, 2nd edn. Savona, Italy: Editrice Dogma, 2003